Role of Spleen Tyrosine Kinase Inhibitors in the Management of Rheumatoid Arthritis

ISSN： 0012-6667

Source： Drugs, Vol.71, Iss.9, 2011-06, pp. : 1121-1132

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 6, 2013-03 ,pp. : 760-773

Bentham Science Publishers

Access to resources Recommend Favorite

Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 – 2013

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 24, Iss. 5, 2014-05 ,pp. : 573-595

Informa Healthcare

Access to resources Recommend Favorite

Structure-based Drugs Design Studies on Spleen Tyrosine Kinase Inhibitors

Letters in Drug Design & Discovery, Vol. 13, Iss. 9, 2016-11 ,pp. : 845-858

Bentham Science Publishers

Access to resources Recommend Favorite

TNF- inhibitors and rheumatoid arthritis

By Shire M.G. Muller G.W.

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 5, 1998-05 ,pp. : 531-544

Informa Healthcare

Access to resources Recommend Favorite

An analysis of the diaminopyrimidine patent estates describing spleen tyrosine kinase inhibitors by Rigel and Portola

By Moore William J Richard David Thorarensen Atli

Expert Opinion on Therapeutic Patents, Vol. 20, Iss. 12, 2010-12 ,pp. : 1703-1722

Informa Healthcare

Access to resources Recommend Favorite